Philips India Unlisted Share

Overview

The parent business of Philips India Limited is Royal Philips of the Netherlands, which is committed to improving people's health and allowing better outcomes across the healthcare ecosystem, from healthy lifestyles and prevention to diagnosis, diagnosis, and home care. Philip India is a well-known high-tech company that specialises in personal and care systems. The company also has a healthcare innovation hub in Pune and a campus for innovation in Bangalore. The business wants to develop significant improvements that will enhance people's well-being and health.

Philips India Limited's Unlisted Share Price are updated on our website on a daily basis, to stay updated with the share price you can visit our website every two days or register with us to get daily updates on WhatsApp.

Philips India FAQ's

Yes trading in unlisted shares is undoubtedly legal in India. The trading takes place in the over-the-counter market through various platforms like www.pmsnstocks.com.

No, SEBI does not regulate the unlisted share market but certain rules and regulations of SEBI are applicable in the unlisted market space as well, such as, the DP charges for each transaction, stamp duty, lock-in period and more.

Over the years the minimum ticket size for investment has dropped as more and more people have started investing in the Unlisted market. Currently, the minimum ticket size for Philips India is between 30K to 50K.

You can check daily share prices of companies on our website or register with us using your phone number where you will get daily whatsapp updates on company news and other essential informations.

Speak to Private Equity Consultant

Confused... How to Pick the Best Stock? Take Advice From Best Private Equity Advisors

Disclaimer: www.pmsnstocks.com is an information portal. www.pmsnstocks.com is not an investment advisory portal and does not make any investment recommendations
and therefore does not require any license from SEBI/RBI or regulatory authority in India.Investors are advised to use the data at their own risks.